Home › Trials › NCT06665815
Clinical trial Recruiting at 1 site Observational Ages 2 to 45

National screening for islet autoantibodies in relatives of type 1 diabetes patients

Official title: A National Screening Program for Islet Autoantibodies Among First-degree Relatives of T1D Patients

Run by Rabin Medical Center · NCT06665815 · Data updated 2026-11-12

This study is testing a screening program for family members of people with type 1 diabetes to see if they have certain autoantibodies that could mean they are at risk of developing the disease.

More Type 1 Diabetes trials

Quick facts

Study typeObservational
Ages2 Years to 45 Years
SexAll
Enrollment20000 (estimated)
SponsorRabin Medical Center
Academic / other
Locations1 site (Petah Tikva)
StatusRecruiting
StartedDecember 15, 2024
Main results expectedDecember 15, 2027
Study endsFebruary 15, 2028
Registry record updatedMay 20, 2025
Trial IDNCT06665815 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are first-degree relatives of individuals with type 1 diabetes, aged between 2 and 45 years.

Probably not a fit

Patients with known diabetes or those currently using systemic immunosuppressive agents will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This program aims to screen first-degree relatives of individuals with type 1 diabetes for the presence of islet autoantibodies, which can indicate pre-clinical stages of the disease. Participants aged 2-45 will be tested for four specific autoantibodies using the ADAP assay, and those with positive results will undergo confirmation testing. The goal is to identify individuals at risk for developing type 1 diabetes and provide them with educational resources to prevent diabetic ketoacidosis (DKA). This observational study will help in understanding the progression of type 1 diabetes in at-risk populations.

Why it matters

Potential benefit: If successful, this program could lead to early identification and intervention for individuals at risk of developing type 1 diabetes, potentially preventing severe complications.

How similar studies have gone: Similar screening programs have shown promise in identifying at-risk individuals, making this approach both relevant and potentially impactful.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age 2-45 years
* First-degree relatives of Type 1 Diabetes probands
* Signing an informed consent

Exclusion Criteria:

* Known diabetes of any kind (type 1, type 2, MODY)
* Have a previous history of being treated with insulin or oral diabetes medications.
* Currently, using systemic immunosuppressive agents (topical and inhaled agents are acceptable)

Where it's running

  • Schneider Children Medical Center of Israel
    Petah Tikva, Israel     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Type 1 Diabetes 495Rabin Medical Center 21
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.